Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Dobutamine
(D03879)		[1] Dobutamine[1] Dobutamine (D03879) 💬[1] ADRB1 💬[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[4] 57, 58, 86, 215 💬
2Dobutamine test
(D03879)		[1] Dobutamine[1] Dobutamine (D03879) 💬[1] ADRB1 💬[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 86 💬
3Post-CPB Drug: Dobutamine Hydrochloride
(D03879)		[1] Dobutamine[1] Dobutamine (D03879) 💬[1] ADRB1 💬[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 58 💬
4Pre and post-CPB Drug: Dobutamine Hydrochloride
(D03879)		[1] Dobutamine[1] Dobutamine (D03879) 💬[1] ADRB1 💬[11] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬[1] 58 💬